Patrick Vink has more than 35 years of experience in the biopharmaceutical industry. He currently serves as Chairman of Essential Pharma and F2G in the UK and is a Board member of SQZ Biotechnologies, Amryt Pharma, Santhera Pharmaceuticals and Spero Therapeutics, based both in Europe and the USA. He also chaired until recently Biognosys AG, NMD Pharma and Targovax and Acacia Pharma. 

While serving at these companies , Patrick has been critically involved in their M&A exits, initial public listings, also achieving meaningful development, regulatory and commercial milestones as well as geographic expansions.

His last operational role was Executive Vice-President and COO of Cubist Pharmaceuticals, a leader in anti-infectives and acute care hospital market until its acquisition by Merck Inc in 2015.

Before his tenure at Cubist he held positions as Senior Vice-President of Global Hospital Business at Mylan Inc. Earlier in his career he held several leadership positions across the industry as Head Global Biopharmaceuticals at Sandoz, Vice-President International operations at Biogen and Head global marketing Cardio-Thrombosis at Sanofi.

Patrick has served as a member of the Executive Committee of EFPIA (European Federation of Pharmaceutical Industry). He graduated as a medical doctor in 1988 at Leiden University, Netherlands and obtained his MBA in 1992 at the University of Rochester.